Neurovascular Unit Dysfunction In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The neurovascular unit (NVU) is a functional ensemble comprising neurons, astrocytes, microglia, pericytes, and endothelial cells that together regulate cerebral blood flow (CBF), maintain the blood-brain barrier (BBB), and ensure proper nutrient and waste exchange. Dysfunction of the NVU is now recognized as a critical contributor to neurodegenerative diseases, particularly Alzheimer's disease (AD), vascular cognitive impairment (VCI), and Parkinson's disease (PD).
flowchart TD
subgraph NVU Components
A[Neurons](/cell-types/neurons) --> B[Astrocytes](/entities/astrocytes)
B --> C[Endothelial Cells](/cell-types/endothelial-cells)
B --> D[Pericytes](/cell-types/pericytes)
C --> E[Blood-Brain Barrier](/entities/blood-brain-barrier)
D --> E
A --> F[Microglia](/entities/microglia)
end
G[NVU Dysfunction] --> H[BBB Breakdown]
G --> I[CBF Dysregulation]
G --> J[Neuroinflammation](/mechanisms/neuroinflammation)
G --> K[Metabolic Impairment]
H --> L[Aβ Clearance Failure]
I --> M[Hypoperfusion]
J --> N[Microglial Activation]
K --> O[Energy Failure]
L --> P[Neurodegeneration]
M --> P
N --> P
O --> P
style G fill:#f9f,stroke:#333
style P fill:#f99,stroke:#333
BBB breakdown is observed in neurodegenerative diseases:
In Alzheimer's Disease:
In Parkinson's Disease:
Key Molecular Players:
Reduced CBF is both cause and consequence of neurodegeneration:
AD:
VCI:
PD:
Mechanisms:
Neurovascular coupling (functional hyperemia) is the process by which increased neuronal activity leads to increased CBF. This is impaired in:
Pericytes are particularly vulnerable:
NVU dysfunction is an early feature of AD:
The "vascular hypothesis" of AD proposes that NVU dysfunction initiates or accelerates amyloid and tau pathology.
VCI represents pure vascular contributions:
NVU dysfunction in VCI:
NVU in PD:
| Target | Approach | Status |
|---|---|---|
| BBB repair | Tight junction modulators | Preclinical |
| Pericyte function | PDGFR-β agonists | Preclinical |
| Cerebral perfusion | Vasodilators | Clinical trials |
| Endothelial health | ACE inhibitors, statins | Clinical |
| Biomarker | Sample | Disease | Interpretation |
|---|---|---|---|
| CSF/serum albumin ratio | CSF, blood | All | BBB permeability |
| MMP-9 | CSF, blood | AD, VCI | Matrix degradation |
| sPDGFRβ | CSF, blood | AD | Pericyte injury |
| VEGF | CSF, blood | AD, PD | Angiogenesis/BBB |
| Qalb | CSF | VCI | BBB breakdown |
NVU dysfunction connects to major neurodegenerative mechanisms:
The study of Neurovascular Unit Dysfunction In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Iadecola C, et al. (2023). The neurovascular unit coming of age. Nature Neuroscience. PMID:37491486
Sweeney MD, et al. (2022). Vascular dysfunction - The disregarded partner of Alzheimer's disease. Alzheimer's & Dementia. PMID:35895273
Montagne A, et al. (2021). Pericyte dysfunction and blood-brain barrier aging. Nature Aging. PMID:34853472
Zlokovic BV, et al. (2023). Neurovascular dysfunction and neurodegeneration. Lancet Neurology. PMID:36868352
Bell RD, et al. (2020). Apolipoprotein E4 and cerebrovascular dysfunction. Nature Reviews Neurology. PMID:32844186
Hachinski V, et al. (2022). Vascular cognitive impairment. Lancet Neurology. PMID:35816625
Guo L, et al. (2021). Neurovascular unit in Parkinson's disease. Molecular Neurodegeneration. PMID:34996418
Arai K, et al. (2020). Neurovascular unit in ALS. Brain Research. PMID:32810456
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 8 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |
Overall Confidence: 36%